Robert S. Rosenson, MD, FACC
Director, Metabolism and Lipids, Mount Sinai Health System, Professor of Medicine
Icahn School of Medicine At Mount Sinai

Printed as of 11/20/2026

Disclosures

Personal Commercial (18)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
89Bio	Research/Research Grants	Significant (>= $5,000)	*Prevention*
Amgen Inc.	Other - *Academic Research Organization (ARO) Agreement - to Institution and Consulting fees*	Significant (>= $5,000)	*Prevention*
Arrowhead Pharmaceuticals, Inc	Research/Research Grants	Significant (>= $5,000)	*Prevention*
AstraZeneca Pharmaceuticals	Other - *ARO Agreement - to Institution*	Significant (>= $5,000)	*Prevention*
Eli Lilly and Company	Research/Research Grants	Significant (>= $5,000)	*Prevention*
General Medicines	Consultant Fees/Honoraria	Modest (< $5,000)	*Prevention*
GSK	Consultant Fees/Honoraria	Modest (< $5,000)	*Prevention*
Kalexo Bio	Other - *Academic Research Funding Organization (ARO) Agreement - to institution*	Modest (< $5,000)	*Prevention*
Lipigon Pharmaceuticals Inc.	Consultant Fees/Honoraria	Modest (< $5,000)	*Prevention*
Mammoth Biosciences	Other - *Academic Research Funding Organization (ARO) Agreement - to institution*	Significant (>= $5,000)	*Prevention*
MediMergent LLC	Stock	Significant (>= $5,000)	*Prevention*
Merck Sharp & Dohme	Research/Research Grants	Modest (< $5,000)	*Prevention*
NIH	Research/Research Grants	Modest (< $5,000)	*Prevention*
Novartis Corporation	Other - *Academic Research Funding Organization (ARO) Agreement to institution and Consulting Fees*	Significant (>= $5,000)	*Prevention*
Novo Nordisk Inc.	Other - *Academic Research Funding Organization (ARO) Agreement - to Institution and Consulting fees*	Modest (< $5,000)	*Prevention*
Rona Therapeutics, Inc.	Other - *Academic Research Funding Organization (ARO) Agreement - to institution and Consulting fees*	Modest (< $5,000)	*Prevention*
Verve Therapeutics	Other - *Research Funding*	Modest (< $5,000)	*Prevention*
Wolters Kluwer	Other - *Royalties*	Significant (>= $5,000)	*Prevention*

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (2)

Non-Commercial Enity Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
CVCT Scientific Program Planning Committee	Other - *Scientific Program Planning Committee Member*	None ($0)	*Prevention*
Novartis Pharmaceuticals	Other - *National coordinator for VICTORION-2-PREVENT Phase 3 clinical trial*	None ($0)	*Prevention*

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 7/29/2026
URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 7/29/2026
URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 7/29/2026
URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 7/29/2026

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.